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Abstract
The existence of multiple inherited disorders of iron metabolism in man, rodents and other vertebrates suggests genetic
contributions to iron deficiency. To identify new genomic locations associated with iron deficiency, a genome-wide
association study (GWAS) was performed using DNA collected from white men aged $25 y and women $50 y in the
Hemochromatosis and Iron Overload Screening (HEIRS) Study with serum ferritin (SF) # 12 mg/L (cases) and iron replete
controls (SF.100 mg/L in men, SF.50 mg/L in women). Regression analysis was used to examine the association between
case-control status (336 cases, 343 controls) and quantitative serum iron measures and 331,060 single nucleotide
polymorphism (SNP) genotypes, with replication analyses performed in a sample of 71 cases and 161 controls from a
population of white male and female veterans screened at a US Veterans Affairs (VA) medical center. Five SNPs identified in
the GWAS met genome-wide statistical significance for association with at least one iron measure, rs2698530 on chr. 2p14;
rs3811647 on chr. 3q22, a known SNP in the transferrin (TF) gene region; rs1800562 on chr. 6p22, the C282Y mutation in the
HFE gene; rs7787204 on chr. 7p21; and rs987710 on chr. 22q11 (GWAS observed P,1.51610
27 for all). An association
between total iron binding capacity and SNP rs3811647 in the TF gene (GWAS observed P=7.0610
29, corrected P=0.012)
was replicated within the VA samples (observed P=0.012). Associations with the C282Y mutation in the HFE gene also were
replicated. The joint analysis of the HEIRS and VA samples revealed strong associations between rs2698530 on chr. 2p14 and
iron status outcomes. These results confirm a previously-described TF polymorphism and implicate one potential new locus
as a target for gene identification.
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Introduction
Iron is essential for life, but excess iron that is not safely bound
to proteins can generate toxic free radicals and consequently body
iron levels are tightly regulated in humans [1,2]. Because humans
do not possess an active mechanism for iron excretion, this
regulation is brought about largely by modulating the uptake of
iron from the diet by the enterocytes of the proximal small
intestine and transfer of this iron to the systemic circulation. The
same factors that regulate iron absorption also regulate release of
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erythropoiesis and other metabolic activities [3]. Iron deficiency is
the most common nutritional disorder in the world with an
estimated four to five billion affected persons [4]. Although often
considered environmental in origin, the existence of multiple
genetic disorders of iron metabolism in man, rodents and other
vertebrates make plausible a genetic contribution to iron
deficiency [5,6,7]. Disorders of iron metabolism underlie some
of the most prevalent diseases in humans and encompass a broad
spectrum of clinical manifestations, ranging from anemia to iron
overload and neurodegenerative diseases [8]. Understanding the
molecular basis of iron regulation in the body is critical for
identifying the underlying causes of each disease entity and
providing proper diagnosis and treatment [8].
We hypothesized that common variants in genes involved in
iron metabolism may modulate susceptibility or resistance to the
development of iron deficiency in humans. A unique multiethnic
population of iron deficient individuals was identified in the
Hemochromatosis and Iron Overload Screening (HEIRS) Study.
In the HEIRS Study, 101,168 participants were screened with
serum biochemical tests of iron status and for common mutations
of the HFE gene [9]. As expected, participants in the HEIRS
Study were identified not only with biochemical evidence of iron
overload but also iron deficiency. To identify genomic locations
associated with iron deficiency, we performed a genome-wide
association study (GWAS) using DNA collected from white
HEIRS Study participants, the largest single group identified by
self-reported race/ethnicity. Case-control status and seven quan-
titative outcomes were examined. These included serum iron (SI),
total iron-binding capacity (TIBC), unsaturated iron-binding
capacity (UIBC), transferrin saturation (TfS), serum ferritin
concentration (SF), serum transferrin receptor (sTfR), and body
iron. Some of these traits are calculated as ratios between basal
trait values; independent outcomes included SI, UIBC, SF, and
sTfR. The association between outcomes and each SNP was
examined. A replication study for the four SNPs showing statistical
significance in the GWAS was conducted in a sample of 71 cases
and 161 controls that were selected from a population of 2559
veterans attending primary care clinics at a Veterans Affairs (VA)
medical center.
Materials and Methods
Study population and replication sample
Approval for the genome-wide association study of iron
deficiency was obtained from the following: Institutional Review
Board of the University of California, Irvine; Institutional Review
Board of the University of California, Berkeley; Institutional
Review Board of the University of Minnesota; Howard University
Institutional Review Board; Institutional Review Board of the
University of Alabama at Birmingham; Institutional Review Board
of Kaiser Permanente Center for Health Research; Institutional
Review Board of Wake Forest University Health Sciences; the
University of Western Ontario Research Ethics Board for Health;
and the Institutional Review Board of the Department of Veterans
Affairs Long Beach Healthcare System. Written informed consent
was obtained from all participants. Samples were collected by the
five HEIRS Field Centers [9,10]. Selection criteria included self-
report of white or Caucasian race/ethnicity only, males at least 25
years of age and females at least 50 years. Females younger than
50 years were excluded because of pre-menopausal iron depletion
from blood loss. The five Field Centers encompassed six
geographic locations including Alabama, California, District of
Columbia, Hawaii, and Oregon in the United States, and Ontario,
Canada. Participants enrolled in the initial screening phase of the
HEIRS Study were eligible if they had not withdrawn consent and
agreed to blood storage. Cases had a serum ferritin concentration
(SF) # 12 mg/L. An equal number of iron-replete Caucasian
controls (SF.100 mg/L in men, SF.50 mg/L in women) were
frequency–matched 1:1 to cases by sex and geographic location.
Replication for SNPs identified from the main GWAS was
conducted in a population attending primary care clinics at a
Veterans Affairs (VA) medical center, the Department of Veterans
Affairs Long Beach Healthcare System. The Institutional review
board reviewed and approved the study. Eligibility within the VA
population was restricted to age as for the HEIRS population
($25 y men and $50 y for women) and to self-reported white
ethnicity. Participants were recruited by first defining a sampling
frame using medical center data on patients who made outpatient
visits to the facility. There were 2559 enrolled in the study (138
women). Those persons with SF#20 mg/L, indicating low iron
stores, were classified as iron-deficient cases. Milman et al. found
that a serum ferritin concentration of 20 mg/L showed the highest
diagnostic efficiency for identifying reduced iron stores [11]. This
threshold, selected to provide an increase in power for replication,
is consistent with recommendations for screening for iron
deficiency in men [12]. Controls were men with SF.100 mg/L
and women with SF.50 mg/L, as for GWAS participants, and
they were frequency matched with cases by sex to achieve two
controls for every case.
Laboratory methods
HFE C282Y and H63D genotypes were determined using the
InvaderH Assay (Third Wave Technologies, Madison WI). Lack of
a detectable C282Y or H63D mutation was designated as HFE
wild-type (wt/wt). For the HEIRS Study, spectrophotometric
measures of serum iron and UIBC levels, turbidometric immuno-
assay of SF (Roche Applied Science/Hitachi 911, Indianapolis,
IN), and calculation of TfS were performed on non-fasting blood
samples. The Central Laboratory, located at University of
Minnesota Medical Center, Fairview, Minneapolis, MN, per-
formed all laboratory tests, except TfS testing of Canadian
participants. These tests were performed at MDS Laboratory
Services, Canada, using an identical method. The detection
threshold of the laboratory instruments for TfS was 3% and values
below this detection threshold were imputed as 1.5%. The serum
ferritin method was optimized to enhance the precision of
measurements within the iron deficient range required for the
calculation of body iron. Serum iron, sTfR, SF, and UIBC were
analyzed using Roche reagents on the Roche/Hitachi Modular P
instrument (Roche Diagnostics, Indianapolis, IN). TIBC was
calculated as the sum of SI + UIBC. TfS was calculated as the
ratio, SI/TIBC, and expressed as a percentage. Body iron (mg/
kg), an index of iron deficiency, was assessed as follows: body iron
= 2[log10((sTfR61000)/SF) 2 2.8229]/0.1207. In this approach,
body iron is expressed as a positive value when stores are present
and negatively with tissue iron deficiency [13,14]. A body iron ,
24 mg/kg body weight represents a deficit severe enough to
produce anemia. However, positive values may occur in some cases
of iron deficiency, for example, when sTfR is not elevated as a
result of a lack of erythropoietin related to co-morbid conditions
such as kidney disease. A body iron ,2 4 mg/kg body weight
represents a deficit severe enough to produce anemia. The sTfR/
SF ratio was calibrated previously by quantitative phlebotomy
performed in healthy subjects [15]. To exclude common
environmental causes of iron deficiency, antibody testing was
performed for H. pylori, carcinoembryonic antigen (CEA), and
celiac disease. The celiac disease screen was performed using a
Genome-Wide Study of Iron Deficiency
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transglutaminase IgA (ttg) was measured. For those samples
showing positive or borderline results for the ttg, an anti-
endomysial antibody (ema-IgA) test was then performed. C-
reactive Protein (CRP), alanine aminotransferase (ALT), and
gamma-glutamyltransferase (GGT) were measured to identify
acute phase protein elevations in SF.
Genome-wide genotyping and quality control
procedures for HEIRS samples
Buffy coat DNA was extracted and purified by SDS cell lysis
followed by a salt precipitation method for protein removal using
commercial PuregeneH reagents (Gentra System, Inc., Minneap-
olis, MN, now Qiagen, Valencia, CA). GWAS genotyping was
performed on 361 cases and 352 controls with the Illumina
HumanCNV370K BeadChip platform. Fourteen cases were
excluded because they had positive test results for celiac disease.
Two cases and one control were excluded because they reported
previous phlebotomy treatment. A total of 348,336 SNPs
(excluding SNPs that are markers specifically for copy number
variants) were assessed for quality. Quality control tests were
carried out using the GenABEL library [16] of the R statistical
package (http://www.r-project.org/). Quality control assessments
resulted in the exclusion of 17,267 SNPs due to at least one of the
following criteria: a minor allele frequency less than 1%, a call rate
less than 95%, rejection of Hardy-Weinberg equilibrium (HWE) at
p-value , 1610
27 (genome-wide corrected p-value ,0.05), or
evidence for SNPs labeled as X-linked actually being autosomal at
odds .1000. Eighteen samples were excluded from the analysis
due to a call rate ,95%, excessive genome-wide heterozygosity,
an average identity-by-state value indicating a first or second
degree relationship between individuals, or misclassification of sex.
After filtering of SNPs and samples, there were 331,060 SNPs
available for analysis in a sample of 336 cases and 343 controls.
Multidimensional scaling of a matrix of identity-by-state (IBS)
distances computed from the SNP genotype data found no
evidence for heterogeneity in ancestry or other outliers.
Genotyping and quality control procedures for
replication samples
DNA was extracted from whole blood aliquots using an
automated nucleic acid purification robotic workstation (MagNA-
Pure, Roche) in combination with magnetic bead-based reagent
technology (LC DNA Isolation kit I, Roche). The total DNA yield
and quality was determined by A260nm and A280nm spectrophoto-
metric readings. The four SNPs included in the replication study
and presented here were included in a set of 60 SNPs that were to
be genotyped on the VA samples. Multiplex design for
SequenomeH MassARRAYH iPLEX Gold platform included 59
out of 60 selected SNPs divided into three multiplexes containing
32, 24 and 3 SNPs, respectively. Two big multiplexes, with 56
SNPs in total, were used for iPLEX genotyping of 238 samples.
SNP call rate was .95% for 232 (97%) samples with one SNP
(rs5925535) failing completely. Each sample was assessed for
completeness of data and genotype data was assessed for
deviations from HWE, allele frequency and completeness. The
four SNPs included in the GWAS replication study passed all of
the quality control assessments.
Statistical analyses
Statistical analyses of the GWAS genotype data were carried out
using the GenABEL library [16] of the R statistical package
(http://www.r-project.org/). The dichotomous case-control out-
come was analyzed using logistic regression and the quantitative
iron status outcomes were analyzed using linear regression.
Genotypes were coded as 0, 1 or 2, indicating the number of
copies of the less frequent of the two alleles in the genotype. The
effect of the additive genotype parameter was estimated assuming
that the variable had a continuous distribution. The odds ratios
reflect the multiplicative increase in risk (for being a case)
attributable to the addition of one copy of the minor allele to
the genotype. A positive linear regression coefficient indicates that
increasing values of the quantitative outcome are associated with
increasing copies of the minor allele in the genotype. The
regression models for all outcomes included the additive genotype
term and the covariates: age, sex and a five-level factor indicating
the center where the sample was collected. Analysis of the follow-
up genotype data was carried out using the SAS package with the
same analytical approach as the GWAS. Significant covariates
were identified by forward stepwise regression. The GWAS and
follow-up combined data analysis was carried out using SAS. Data
from males and females were pooled, for sample size consider-
ations, and regression models included the additive genotype term,
age, sex and a six-level factor indicating the sample source.
Missing genotypes and genotypes from unmeasured SNPs
across the two regions were imputed using the program MACH
1.0 [17]. Phased haplotypes were downloaded from the HapMap
database (http://www.hapmap.org) as input for the imputation.
The estimated allele dose for each imputed SNP was analyzed as
described for the measured SNPs. The allele dose was the product
of the computed posterior probability of each genotype given the
measured genotype data and the HapMap phased haplotype data
and the allele dose for the genotype (0, 1 or 2 reflecting the
number of minor alleles in the genotype), summed over the three
possible genotypes.
Results
Genome-wide Association Study
Following quality control analyses, the genome-wide association
analysis with 331,060 SNP genotypes was conducted on 336 iron
deficient cases and 343 normal controls. The outcomes analyzed
for association included the dichotomous case-control status and
the seven iron-related quantitative phenotypes. Natural log
transformations were applied to SF, TfS, and sTfR variables to
correct for positive skewness and improve the fit to the normal
distribution. Loge(SF) and body iron showed bimodal distributions
that reflected the definition of the iron deficient case-control
outcome. Table 1 shows the characteristics of the quantitative
variables by case-control status for the HEIRS GWAS sample. All
of the variables were significantly associated with iron deficiency
case-control status (p-value,0.001).
The full GWAS results for the eight iron status outcomes are
presented graphically in the Manhattan plots shown in Figure 1.
The patterns observed across the panel figures illustrate the
correlations between the outcomes. Genome-wide statistical
significance was defined as a SNP showing a p-value for
association less than 1.51610
27 for at least one of the eight iron
outcomes; the threshold is based on a nominal alpha of 0.05 with
Bonferroni multiple test correction for the total number of SNPs
analyzed. No additional multiple test correction was made for the
analysis of the correlated iron status outcomes. Table 2 shows the
association results for the five SNPs meeting genome-wide
statistical significance. The table shows the results for the outcome
that showed the statistically significant association as well as any of
the other iron status outcomes that were associated with the SNP
at a p-value less than 0.01 (observed). The SNP rs2698530 on
Genome-Wide Study of Iron Deficiency
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(observed p-value=5.96610
28, corrected p-value=0.02) and
approached genome-wide statistical significant associations with
Loge(TfS) (observed p-value=3.70610
27, corrected p-val-
ue=0.12) and TIBC (observed p-value=5.01610
27, corrected
p-value=0.17). The additional five iron outcomes showed
associations with rs2698530 at p-values ranging from 2.29610
25
(body iron) to 1.88610
24 (serum iron).
The SNP rs3811647 in the TF gene on chromosome 3q22.1
showed a significant association with TIBC (observed p-
value=7.00610
29, corrected p-value=0.0023). The SNP also
showed an observed p-value of 7.78610
25 for association with
UIBC that did not meet genome-wide statistical significance and
there was no evidence for association with any of the six other iron
status outcomes. The SNP rs7787204 on chromosome 7p21.3
showed a statistically significant association with Loge(sTfR)
(observed p-value=7.30610
28, corrected p-value=0.024). For
this SNP, six of the other iron outcomes had observed p-values of
less than 0.01, with body iron (p-value=8.93610
26) and iron
deficient case-control status (p-value=3.49610
25) showing the
smallest observed p-values of the six outcomes. The SNP rs987710
on chromosome 22q11.22 showed a significant association with
Loge(SF) (observed p-value=1.40610
27, corrected p-val-
ue=0.046) and nearly met the threshold for genome-wide
significance with iron deficient case-control status (observed p-
value=2.13610
27, corrected p-value=0.071) and body iron
(observed p-value=2.21610
27, corrected p-value=0.073). The
five remaining iron outcomes showed marginal evidence for
association with the SNP.
The SNP rs1800562 on chromosome 6p22.2 is the C282Y
mutation in the HFE gene and is known to affect iron
metabolism. The SNP met genome-wide statistical significance
for association with TIBC (observed p-value=1.31610
27,
corrected p-value=0.043) and nearly reached genome-wide
statistical significance for UIBC (observed p-value=3.15610
27,
corrected p-value=0.10), and showed marginal evidence for
association with serum iron (observed p-value=0.0091) and
Loge(TfS) (observed p-value=0.005). The known iron overload
mutation did not show statistically significant evidence for
association with iron deficient case-control status, body iron,
Loge(SF) and Loge(sTfR), even at a nominal alpha level of 0.01.
The allele frequency of the mutation in the full GWAS sample
was 0.074 with case and control frequencies of 0.063 and 0.085
respectively.
The genomic control parameters (i.e., lambda) computed from
the case-control association statistics was 0.996 (SE=0.00002)
indicating that no genome-wide inflation of the association
statistics was present. Genomic control parameters were also
computed for the loge(SF) and body tissue iron outcomes because
the variables showed bimodal sample distributions which would
result in a violation of the assumption of normally distributed
residual errors in the linear regression analysis and the potential
for an incorrect false positive rate. Neither of the two outcomes
showed evidence for a significant deviation from the expected null
distribution with both having genomic control parameters of 1.002
(SE,0.0001).
Follow-up Association Study
A follow-up sample of 71 white iron deficient cases (61 males, 10
females) and 161 matched controls (134 males, 27 females) from
the Department of Veterans Affairs Long Beach Healthcare
System was used to assess replication of the GWAS findings.
Table 1 shows the characteristics of the quantitative iron outcomes
by case-control status. All variables were significantly associated
with case-control status (p,0.001). Table 2 shows the results of the
association analysis of the follow-up sample for the four SNPs that
showed significant associations in the GWAS as well as the C282Y
mutation. The SNPs in the follow-up analysis were tested for
association with statistical models that included age and sex so the
results would be comparable to the GWAS. Using the SF
threshold of 20 for case definition may have introduced more
heterogeneity in samples and possibly increased the false negative
rate for detection of association with iron measures; however, the
criteria for replication of association was still achieved for several
SNPs. The follow-up analysis of rs2698530 (chr. 2p14), rs3811647
(TF) and rs1800562 (HFE) showed evidence for association with an
observed p-value less than 0.05 with an iron outcome that met or
nearly met the genome-wide significance level in the GWAS. The
SNP rs2698530 showed observed p-values of 5.01610
27 and
0.032 for association with TIBC in the GWAS and follow-up
analyses, respectively. P-values of 7.0610
29 and 0.012 were
Table 1. Descriptive statistics of the GWAS and replication
sample phenotypes.
Measure
a Status Mean SD Min Max
HEIRS GWAS Sample (336 Cases, 343 Controls)
Body iron Case 22.00 2.38 210.04 2.40
Control 10.82 2.50 5.71 19.31
Serum iron (mg/dL) Case 52.5 27.80 11.0 173.0
Control 89.65 29.32 22.0 189.0
Loge(SF) (mg/L) Case 2.15 0.32 ,0.01 2.57
Control 4.96 0.61 3.95 6.73
Loge(TfS) (%) Case 2.44 0.58 1.10 3.71
Control 3.31 0.36 1.61 4.49
Loge(sTfR) (mg/L) Case 1.71 0.45 0.53 3.29
Control 1.05 0.30 0.10 2.00
TIBC (mg/dL) Case 402.2 52.10 263.0 593.0
Control 312.4 46.79 97.0 442.0
UIBC (mg/dL) Case 349.7 62.76 185.0 554.0
Control 222.7 52.89 21.0 384.0
VA Replication Sample (71 Cases, 161 Controls)
Body iron Case 20.24 2.72 27.88 6.01
Control 11.04 2.78 4.74 20.9
Serum iron (mg/dL) Case 71.4 40.6 15.0 258.0
Control 92.4 38.7 19.0 263.0
Loge(SF) (mg/L) Case 2.32 0.58 0.69 3.00
Control 5.34 0.69 3.93 7.47
Loge(TfS) (%) Case 2.80 0.60 1.13 4.26
Control 3.26 0.40 1.93 4.51
Loge(sTfR) (mg/L) Case 2.02 0.44 0.92 3.54
Control 1.85 0.40 0.64 2.98
TIBC (mg/dL) Case 384.5 67.20 253.7 577.6
Control 334.2 61.1 164.2 597.1
UIBC (mg/dL) Case 313.1 88.0 90.4 547.6
Control 241.8 65.1 26.5 536.1
aQuantitative measure (abbreviation): serum ferritin concentration (SF),
transferrin saturation (TfS), serum transferrin receptor (sTfR), total iron-binding
capacity (TIBC), unsaturated iron-binding capacity (UIBC).
doi:10.1371/journal.pone.0017390.t001
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GWAS and follow-up studies, respectively. UIBC and TIBC both
showed evidence for association with the C282Y mutation in the
follow-up study, with p-values of 0.0004 and 0.035, respectively.
The SNPs rs7787204 on chromosome 7p21.3 and rs987710 on
22q11.22 did not show any evidence for association and failed to
replicate in the follow-up sample.
Association Analysis of Combined GWAS and Follow-up
Samples
The GWAS and follow-up study data were combined and the
five SNPs shown in Table 2 were analyzed for each of the
outcomes in a regression model that included age, sex and the
collection center variable. The results of the combined analysis are
consistent with the follow-up study. Genome-wide significance was
found for the association of rs2698530 (chr. 2p14) with UIBC
(observed p-value=1.40610
27, corrected p-value=0.046) and
statistical significance was nearly met with TIBC (observed p-
value=1.67610
27, corrected p-value=0.055). Significant associ-
ation between rs3811647 in the TF gene and TIBC was found in
the combined sample (observed p-value=4.50610
210, corrected
p-value=0.00015). The C282Y mutation in the HFE gene showed
significant associations with UIBC (observed p-val-
ue=5.72610
210, corrected p-value=0.00019) and TIBC (ob-
served p-value=2.68610
28, corrected p-value=0.0089) in the
combined sample.
High-Resolution Association Analysis of Chromosomes
2p14 and 3q22
The strongest statistical evidence for association was found at
SNPs on chromosomes 2p14 and 3q22. In order to map the
associations within the two regions with higher resolution,
genotypes from sets of measured SNPs across the two regions
were used to impute unmeasured genotypes so that a higher
density of SNPs could be analyzed. The significantly associated
SNPs in both regions were observed within single blocks of high
linkage disequilibrium (LD) that were bounded by recombination
hotspots. The high-resolution analysis included the complete
blocks of high linkage disequilibrium where the significantly
associated SNPs were located and extended tens of kbp into the
neighboring blocks on each side. For chromosome 2, the fine
resolution analysis extended over approximately 128 kbp. The
high-resolution analysis of chromosome 3 included a region of
approximately 279 kbp; however, the results are presented for
32.5 kbp of this region in order to better illustrate the important
results. The genomic positions are based on the March 2008
human reference sequence (NCBI Build 36.3).
Figure 2 shows the results of the high-resolution association
analysis of TIBC and UIBC across the 127,705 bp region of
chromosome 2p14. The analysis included 117 SNPs; 21 SNPs
were measured and analyzed in the GWAS and the remaining 96
SNPs were generated using imputation. The most significant
results were found at SNPs that were part of the GWAS. For
UIBC the most significant association was at rs2698530 (observed
p-value=8.31610
28) and for TIBC it was at rs2698527 (observed
p-value=2.73610
27). A continuous set of eight SNPs showed –
log10(p-values) greater than 6.0 (i.e., p-value,1.0610
26) for
association with both UIBC and TIBC, spanning 15,216 bp,
bounded by rs2698541 and rs2698530. The region contains no
known genes. Pair-wise D’ LD measures were computed from all
of the SNPs included in the high-resolution association analysis
and were presented in the two-dimenional graph shown under the
association results. The graph clearly shows that the LD block
boundaries are consistent with the association results with steep
drops in the statistical significance of the association results
occurring at the boundaries of the high-LD block.
The high-resolution association analysis of chromosome 3q22
included 40 SNPs measured in the GWAS and 220 imputed SNPs
distributed across a 279,147 bp region. Figure 3 shows the results
from the analysis of TIBC and UIBC across 32,500 bp of the full
region analyzed. The location and structure of the TF gene is
shown across the top of the figure. The most significant association
with both outcomes was observed with the measured SNP
rs3811647, with observed p-values of 9.55610
29 and
7.28610
26 for TIBC and UIBC, respectively. The most
statistically significant associations with TIBC and UIBC were
observed at five SNPs across a 7,011 bp region. The region
included one measured SNP (rs3811647) and four imputed SNPs
(rs8177240, rs8177252, rs8177272 and rs1525892). The 7 kbp
region includes exons 9, 10 and 11 of the TF gene.
Discussion
In this genome-wide association study of participants in the
HEIRS Study, analyses of data from iron-deficient cases and iron-
replete controls identified five SNPs associated with at least one of
the quantitative iron measures at an observed p-value less than
1.51610
27 (genome-wide corrected p-value,0.05). These SNPs
included rs2698530 on chr. 2p14, rs3811647 in the TF gene on
chr. 3q22, rs1800562 on chr. 6p22 (the known C282Y mutation in
HFE), rs7787204 on chr. 7p21, and rs987710 on chr. 22q11.
Replication of the association with TIBC in an independent VA
population was demonstrated for rs3811647 (observed P=0.012)
and for rs1800562 in HFE (observed P=0.035). In the joint
analysis, combining HEIRS and VA datasets, the strongest
statistical significance with iron-related measures was found at
rs3811647 in the TF gene for association with TIBC (observed
P=4.50610
210). The joint analyses also revealed strong associ-
ations between rs2698530 on chr. 2p14 and two iron status
outcomes, TIBC and UIBC. High-resolution association analyses
of TIBC and UIBC across a 127,705 bp region of 2p14 containing
rs2698530 and a 279,147 bp region of 3q22 containing rs3811647
indicated that the most significant results were found at measured
SNPs in the GWAS for association with UIBC (rs2698530,
observed P=8.31610
28 Fig. 2) and with TIBC (rs3811647,
observed P=9.55610
29, Fig. 3).
The quantitative iron-related measures examined here were
significantly associated with iron deficiency in the GWAS
(p,0.001) and in the VA follow-up sample (p,0.001), and a
high degree of concordance was observed in the results across the
quantitative traits. This was expected as TfS is calculated from the
measured values of serum iron and UIBC, and body iron is
estimated from sTfR and SF. Total iron binding capacity
measures the blood’s capacity to bind iron with transferrin, and
values are expected to be higher in individuals with iron
deficiency, compared to those who are iron replete [18]. This
relationship was borne out in the current study, with higher TIBC
values in the cases than in the controls. In the GWAS and follow-
up studies, we used TIBC as a marker for transferrin. For purposes
Figure 1. Manhattan plots displaying results from GWAS for eight iron outcomes. (A) iron deficient case-control status, (B) body iron (C)
serum iron, (D) Loge(SF), (E) Loge(TfS), (F) Loge(sTfR), (G) TIBC, and (H) UIBC.
doi:10.1371/journal.pone.0017390.g001
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GWAS
b Follow-up Study
b Combined
Chromosome, SNP Minor Position Associated % Variance
Gene Allele Outcome
a Estimate
c P-value Estimate
c P-Value Or O.R. P-Value
Chr2p14 rs2698530 C 64357399 Case-Control 1.68 7.86610
25 0.85 0.52 1.44 (O.R.) 0.0014
Body Iron 21.81 2.29610
25 20.20 0.76 1.5 0.00019
Serum Iron 27.94 1.88610
24 2.02 0.66 0.7 0.0083
Loge(SF) 20.36 8.23610
25 0.03 0.85 1.0 0.0018
Loge(TfS) 20.20 3.70610
27 20.02 0.71 2.3 3.51610
26
Loge(sTfR) 0.12 1.63610
24 0.12 0.013 1.6 4.00610
25
TIBC 20.72 5.01610
27 16.27 0.032 3.0 1.67610
27
UIBC 28.75 5.96610
28 14.25 0.11 3.0 1.40610
27
Chr3q22.1, TF rs3811647 A 134966719 Case-Control 1.07 0.58 0.91 0.65 1.08 (O.R.) 0.44
Body Iron 20.28 0.48 0.16 0.78 0.03 0.60
Serum Iron 20.19 0.92 7.88 0.045 0.11 0.31
Loge(SF) 20.06 0.48 20.04 0.79 0.07 0.42
Loge(TfS) 20.06 0.088 0.05 0.32 0.15 0.24
Loge(sTfR) 0.02 0.58 20.07 0.096 0.02 0.68
TIBC 21.49 7.00610
29 16.69 0.012 4.2 4.50610
210
UIBC 21.62 7.78610
26 8.81 0.26 2.2 8.35610
26
Chr6p22.2, HFE rs1800562 A 26093141 Case-Control 0.76 0.19 0.68 0.24 0.89 0.53
Body Iron 1.43 0.042 0.75 0.41 0.55 0.022
Serum Iron 9.07 0.0091 21.16 0.0005 1.9 1.93610
25
Loge(SF) 0.31 0.039 0.06 0.81 0.41 0.047
Loge(TfS) 0.19 0.005 0.22 0.0066 1.5 0.00016
Loge(sTfR) 20.08 0.12 20.17 0.0072 0.31 0.074
TIBC 235.36 1.31610
27 221.58 0.035 3.4 2.68610
28
UIBC 244.27 3.15610
27 242.7 0.0004 4.1 5.72610
210
Chr7p21.3 rs7787204 G 9847296 Case-Control 2.25 3.94610
25 1.01 0.98 1.86 (O.R.) 0.00015
Body Iron 22.72 8.93610
26 0.21 0.82 1.8 4.24610
25
Serum Iron 26.99 0.023 21.08 0.86 0.50 0.03
Loge(SF) 20.52 9.29610
25 0.06 0.80 1.2 0.00075
Loge(TfS) 20.18 0.0016 20.05 0.50 1.2 0.0011
Loge(sTfR) 0.24 7.30610
28 20.02 0.79 0.7 0.0071
TIBC 19.44 0.0011 13.45 0.18 1.4 0.00029
UIBC 26.46 5.83610
24 14.53 0.22 1.6 0.00015
Chr22q11.22 rs987710 G 22512415 Case-Control 0.54 2.13610
27 0.85 0.48 0.60 (0.R.) 1.28610
26
Body Iron 2.01 2.21610
27 0.76 0.20 2.7 5.23610
27
Serum Iron 5.68 0.0036 3.76 0.35 0.8 0.0069
Loge(SF) 0.44 1.40610
27 0.19 0.22 2.5 1.16610
26
Loge(TfS) 0.12 0.0018 0.10 0.043 1.3 0.00044
Loge(sTfR) 20.11 1.73610
24 20.05 0.26 0.6 0.011
TIBC 210.22 0.0073 28.33 0.20 0.8 0.0059
UIBC 215.93 0.0012 212.08 0.12 1.2 0.00088
aQuantitative measure (abbreviation): serum ferritin concentration (SF), transferrin saturation (TfS), serum transferrin receptor (sTfR), total iron-binding capacity (TIBC),
unsaturated iron-binding capacity (UIBC).
bFor analysis of the GWAS genotype data, the regression models for all outcomes included the additive genotype term and the covariates, age, sex and a five-level
factor indicating the center where the sample was collected. For analysis of the follow-up genotype data, the regression models for all outcomes included the additive
genotype term and the covariates, age and sex.
cFor case-control analyses only, the odds ratios estimate the odds in favor of being iron deficient (over being iron replete) among those participants who have one
additional minor allele, divided by the odds of being iron deficient among those without the additional minor allele. For all other outcomes, a positive linear regression
coefficient indicates that increasing values of the quantitative outcome are associated with increasing copies of the minor allele in the genotype.
doi:10.1371/journal.pone.0017390.t002
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concentration may be used interchangeably. The parameter
estimate was positive for rs3811647 (chr. 3q22) in the regression
on TIBC, indicating that increasing values of TIBC are associated
with increasing copies of the minor allele in the rs3811647
genotype. In contrast, for the regression of rs987710 (chr. 22q11)
on TIBC, the parameter estimate was negative, indicating that
decreasing values of TIBC are associated with increasing copies of
the minor allele.
In humans, strong evidence supporting the presence of genetic
modifiers of iron metabolism was reported by Whitfield and
colleagues who studied a sample of both monozygotic and
dizygotic twin pairs and showed that the pattern of residual
variation in serum iron indices, after adjusting for an effect of the
C282Y mutation, was consistent with the additive effects of
multiple genes [19]. After correcting for age and body-mass index
they estimated that the proportion of variance explained by
additive genetic factors, for men and women respectively, Genetic
Figure 2. High resolution association analysis of GWAS samples for chromosome 2p14. Analysis includes measured genotypes from 21
SNPs and imputed genotypes from 108 SNPs. A. Genome-wide statistical significance is represented by the dashed line corresponding to an observed
p-value of 1.51610
27. For unsaturated iron-binding capacity (UIBC), the most significant association was with rs2698530 (m) with an observed p-
value=8.31610
28. For total iron-binding capacity (TIBC), the most significant association was with rs2698527 (N) with an observed p-
value=2.73610
27. B. The heat graph was generated from pairwise LD coefficients D’, calculated from the HapMap genotype data for all 129 SNPs.
Recombination hotspots are indicated by black bars. C. The location of the region on chromosome 2p14, with approximate position and size of neary
genes is shown.
doi:10.1371/journal.pone.0017390.g002
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terms of association with iron status [20,21,22,23,24]. A study by
Milet and colleagues of a cohort of 592 unrelated C282Y
homozygous probands who attended the Liver Unit in Rennes,
France, was the first to show strong evidence for an association
between a measured common genetic variant, a SNP in the BMP2
gene, and the serum ferritin levels of C282Y homozygotes [25].
BMP6 has recently been shown to be the key endogenous regulator
of hepcidin [26,27,28,29]. Mutations in the TMPRSS6 gene,
another upstream regulator of hepcidin, have been implicated in
iron-refractory iron deficiency anemia through linkage studies
[30,31,32], although these results are based on a few extended
pedigrees and may have limited relevance at the population level.
Mutations in many other genes are known to cause serious
disruption of normal iron metabolism (e.g. HFE2, HAMP,
SLC40A1, TFR2) but the causal mutations are very rare [33].
Constantine et al reported an association between SNP rs884409 in
CYBRD1 and serum ferritin levels measured in HFE C282Y
homozygotes [34]. In our study, this SNP was not available for
assessment in the GWAS as it was not included on the
HumanCNV370K BeadChip.
Further evidence of genetic influences on iron status was found
in a recent study that investigated genetic effects on markers of
iron status using a cohort of twins and their siblings. A GWAS was
conducted on four serum markers of iron status (serum iron,
transferrin, transferrin saturation and serum ferritin) [35]. Along
with confirming previously reported associations of HFE C282Y
on all four markers, these investigators found strong associations
between serum iron and a TMPRSS6 SNP (rs4820268), and
between serum transferrin and several TF SNPs (rs3811647,
rs1358024, rs452586) [35]. The SNP rs452586 was not in our
GWAS dataset. In our study, we found a significant association
between TIBC and rs3811647, but no significant association was
found with rs1358024. We examined linkage disequilibrium
between rs3811647 and rs1358024. The D’ estimate of 1.0 for
this SNP pair indicates very strong linkage disequilibrium,
however the r
2 estimate of 0.39 indicates that the SNPs poorly
predict their corresponding genotypes and respective associations
with the iron phenotypes. An association between SNPs in
TMPRSS6 and serum iron (rs855791) and transferrin saturation
has been found in adolescent and adult individuals [36]. Variants
in TMPRSS6 also have been associated with hemoglobin levels in
individuals of both European and Indian Asian ancestry [37].
Tanaka and colleagues investigated genetic variants associated
with iron concentrations in persons not affected by overt genetic
disorders of iron metabolism. They conducted a GWAS and
confirmed that rs855791 on exon 17 of TMPRSS6 and rs4820268
on exon 13 were strongly associated with lower serum iron
concentration, lower mean corpuscular volume, lower hemoglobin
levels, and higher red blood cell distribution width [38]. In
contrast, we found no genome-wide statistically significant
associations between TRMPRSS6 SNPs and iron-related traits in
the current study. This may be related to our study design that
selected iron-deficient and control groups. Use of a group that
represents one extreme of the population may have masked the
effect of TMPRSS6 SNPs as reflected in a shift in the distribution of
iron status measures of a large number of participants in a general
population study. As complete blood count values were not
collected in the screening phase of the HEIRS Study, we did not
examine associations between SNPs and erythrocyte parameters.
It has been shown that heterozygosity or homozygosity for the
C282Y variant of the HFE gene protects against the development
of iron deficiency [39,40,41,42]. In the present study, we
examined the associations between iron-related measures and
SNP rs1800562, the C282Y mutation of the HFE gene. Illustrating
a protective effect, increasing copies of the minor allele in the
C282Y genotype were associated with decreasing values of TIBC
and UIBC in the GWAS (observed P,3.15610
27 for both), the
VA follow-up study (observed P,0.04 for both), and the combined
sample (observed P,3.0610
29 for both). The C282Y genotype
was estimated to account for 2.0% and 3.4% of the variance in the
TIBC and UIBC traits, respectively.
A limitation to this GWAS may be the relatively small number
of cases with iron deficiency determined through screening of
Figure 3. High resolution association analysis of GWAS samples for chromosome 3q22. The analysis includes measured genotypes from
40 SNPs and imputed genotypes from 220 SNPs. The location and structure of the TF gene is shown along the top of the figure. The most significant
associations with total iron-binding capacity (TIBC,N) and unsaturated iron-binding capacity (UIBC, m) were observed with the measured SNP
rs3811647, with observed p-values of 9.55610
29 and 7.28610
26 for TIBC and UIBC, respectively. The most statistically significant associations were
observed at five SNPs across the 7 kbp region (delineated) which includes exons 9, 10, and 11 of the transferrin gene, TF.
doi:10.1371/journal.pone.0017390.g003
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criteria for genome-wide significance for association with iron-
related measures. Of these, replication on the basis of analyses with
adjustment for age and sex was achieved for the positive association
between TIBC and the number of copies of the less frequent allele
for SNP rs3811647, located on chr. 3q22, and a strong negative
association with increasing number of copies of the less frequent
allele of the C282Y mutation of the HFE gene. For the replication
studies, a threshold of SF#20 mg/L was used to classify cases of
iron-deficiency. This clinically relevant threshold for men was
selected to provide an increase in power for replication. It is possible
that this may have introduced more heterogeneity in samples and
may have resulted in an increase in the false negative rate for
detection of association with iron measures. However, even though
this conservative approach was taken, the criteria for replication of
association were achieved for some SNPs.
Another limitation may be that it is unknown how likely genetic
variants are to affect the variance of the measures used for
determining iron status rather than the actual total body iron.
Additionally, serum ferritin concentration, used to determine case
status, is known to be correlated with other quantitative traits
assessed in the study. It is possible that this, along with the selective
genotyping of individuals from the high and low phenotypic tails of
the populations, may have introduced some bias. For example,
Darvasi and Soller demonstrated in linkage analyses that the
observed difference in quantitative trait values associated with
alternative marker genotypes in a selected population can be
greater than the actual gene effect at the quantitative trait locus
when the entire population is considered [43]. However, the case-
control design of the current study offered the opportunity to
examine specifically the question whether the TF gene SNP
rs3811647 on Chr. 3q22 has an effect on iron status and our
results suggest that it does not.
Our study design differs from previously reported studies in that the
GWAS was conducted on samples from iron-deficient and control
groups identified through population-based screening of participants.
In addition, serum specimens from both sources were tested to
exclude common environmental causes of iron deficiency and causes
of acute phase protein elevations in serum ferritin. A key finding in the
current study is that, although the rs3811647 SNP in TF was
associated with TIBC (and, to a lesser extent, UIBC), it was not
associated with other measures of body iron status or case-control
status. These results do not support the concept of a role for this TF
SNP in regulation of iron metabolism. Thus, this SNP may instead
affect TIBC independently of iron status. Use of TIBC as an index of
iron deficiency may be confounded by the existence in the population
of the rs3811647 minor allele, resulting in an elevated TIBC without a
corresponding increase in body storage iron. With respect to the
rs1800562 SNP in HFE on Chr 6p22.2, we note that the four
associated iron measures are serum iron, transferrin saturation, TIBC,
and UIBC. It is recognized that mean levels of transferrin saturation
(which is calculated from the ratio of serum iron to TIBC or the ratio
of serum iron to the sum of serum iron and UIBC) are elevated in
individuals with one copy of this SNP [39,44]. However these
individuals rarely have any clinically significant increase in body iron
stores [39], so the lack of association with other markers of body iron
status such as measurements of serum ferritin and serum transferrin
receptor is not surprising. It is only individuals who are homozygous
for SNP rs1800562 on chromosome 6p22.2, the C282Y mutation in
the HFE gene, in which an increase in iron stores is likely to occur. In
the HEIRS cohort there were only two cases and four controls who
were homoyzygous for the C282Y mutation. The VA cohort
contained one case and four controls who were C282Y homozygotes.
In summary, this study confirmed the previously identified
rs3811647 in the TF gene on chr. 3q22 and rs1800562, the C282Y
mutation in the HFE gene. Genome-wide association with UIBC
was demonstrated for one new locus identified in the GWAS,
rs269853 on chr. 2p14; however evidence of replication was
marginal in the analysis of an independent VA population.
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